NCT07304154

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2026-04-10Est. Completion: 2029-06

Enrollment target: 52 participants

Locations

Stanford Neuroscience Health Center, Palo Alto, California, United States
LDS Hospital - Intermountain Health, Salt Lake City, Utah, United States
Fred Hutchinson Cancer Center, Seattle, Washington, United States
Concord Repatriation General Hospital, Sydney, New South Wales, Australia

Contact

Medical Informationmedinfo@kitepharma.com 844-454-5483(1-844-454-KITE)

Other microbiome trials you might be interested in

A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating PolyradiculoneuropathyPhase 2Recruiting

Chronic Inflammatory Demyelinating PolyradiculoneuropathyCIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)CIDPChronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

The main purpose of the study is to determine the correct dose of empasiprubart in adolescent participants. It also aims…

Multiple LocationsEst. completion Apr 2028

View Trial →

Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart DevicesRecruiting

CIDP - Chronic Inflammatory Demyelinating Polyneuropathy

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disease that affects the peripheral nerves…

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.